Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2023 at "Blood"
DOI: 10.1182/blood.2022017333
Abstract: Activation of apoptosis in malignant cells is an established strategy for controlling cancer and is potentially curative. To assess the impact of concurrently inducing the extrinsic and intrinsic apoptosis-signaling pathways in acute myeloid leukemia (AML),… read more here.
Keywords: myeloid leukemia; plus venetoclax; eftozanermin alfa; acute myeloid ... See more keywords
Pharmacodynamic effects in blood and tumor tissue of eftozanermin alfa, a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e15668
Abstract: e15668Background: Eftozanermin alfa (eftoza; formerly known as ABBV-621), a 2nd-generation tumor necrosis factor-related apoptosis-inducing ligand receptor agonist, is being evaluated in previously... read more here.
Keywords: factor related; related apoptosis; eftozanermin alfa; tumor necrosis ... See more keywords